Daratumumab（Anti-CD38 Monoclonal Antibody） is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is Institute of Hematology & Blood Diseases Hospital, China. The most-studied condition is Immune Thrombocytopenia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362199 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Daratumumab（Anti-CD38 Monoclonal Antibody） as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Institute of Hematology & Blood Diseases Hospital, China. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Daratumumab（Anti-CD38 Monoclonal Antibody） works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Daratumumab（Anti-CD38 Monoclonal Antibody） works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Daratumumab（Anti-CD38 Monoclonal Antibody） (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.